William K. Grogan - 01 Mar 2026 Form 4 Insider Report for Xylem Inc. (XYL)

Role: EVP & Chief Financial Officer
Signature: /s/ Mike Nazario, by power of attorney for William K. Grogan
Issuer symbol: XYL
Transactions as of: 01 Mar 2026
Net transactions value: +$3,226,177
Form type: 4
Filing time: 03 Mar 2026, 16:53:47 UTC
Previous filing: 18 Sep 2025
Next filing: 06 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Grogan William K	EVP & Chief Financial Officer	C/O XYLEM INC., 301 WATER STREET SE, WASHINGTON	/s/ Mike Nazario, by power of attorney for William K. Grogan	03 Mar 2026	0001694002

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XYL	Common Stock	Award	$715,968	+5,551	+20%	$128.98	33,801	01 Mar 2026	Direct	F1, F2
transaction	XYL	Common Stock	Award	$591,115	+4,583	+14%	$128.98	38,384	01 Mar 2026	Direct	F3
transaction	XYL	Common Stock	Award	$402,031	+3,117	+8.1%	$128.98	41,501	01 Mar 2026	Direct	F4
transaction	XYL	Common Stock	Award	$0	+5,116	+12%	$0.000000	46,617	02 Mar 2026	Direct	F5
transaction	XYL	Common Stock	Tax liability	$759,434	-5,888	-13%	$128.98	40,729	02 Mar 2026	Direct	F6
transaction	XYL	Common Stock	Tax liability	$74,550	-578	-1.4%	$128.98	40,151	02 Mar 2026	Direct	F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	XYL	Non-Qualified Stock Option (Right to Buy)	Award	$2,351,047	+18,228		$128.98	18,228	02 Mar 2026	Common Stock	18,228	$128.98	Direct	F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the acquisition of 5,551 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Total Shareholder Return.
F2	Includes additional shares due to dividend reinvestment.
F3	Reflects the acquisition of 4,583 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Adjusted EBITDA.
F4	Reflects the acquisition of 3,117 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Revenue.
F5	Reflects an award of restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one third increments on March 1, 2027, March 1, 2028 and March 1, 2029.
F6	Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February, 24 2016).
F7	Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of restricted stock units granted on March 1, 2024 (578) under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016).
F8	Reflects an award of non-qualified stock options pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one-third increments on March 1, 2027, March 1, 2028 and March 1, 2029.